Next Article in Journal
Thioredoxin and Cancer: A Role for Thioredoxin in all States of Tumor Oxygenation
Next Article in Special Issue
Modulation of Radiation-Induced Genetic Damage by HCMV in Peripheral Blood Lymphocytes from a Brain Tumor Case-Control Study
Previous Article in Journal
Biology of Human Cutaneous Melanoma
Previous Article in Special Issue
Overexpression of Periostin and Lumican in Esophageal Squamous Cell Carcinoma
Review

Cancer Biomarkers: Are We Ready for the Prime Time?

by 1, and 2,*
1
Institute of Cytology and Preventive Oncology, Division of Molecular Oncology, Noida, 201301, UP, India
2
Methods and Technologies Branch, Epidemiology and Genetics Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute, National Institues of Health (NIH), 6130 Executive Blvd., Suite 5100, Bethesda, MD 20892-7324, USA
*
Author to whom correspondence should be addressed.
Present address: Lab Molecular Biology, NCI, NIH, Bethesda, MD 20892, USA.
Cancers 2010, 2(1), 190-208; https://doi.org/10.3390/cancers2010190
Received: 20 February 2010 / Revised: 2 March 2010 / Accepted: 19 March 2010 / Published: 22 March 2010
(This article belongs to the Special Issue Biomarkers: Oncology Studies)
A biomarker is a characteristic that is objectively measured and evaluated as an indicator of normal biologic processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention. In cancer, a biomarker refers to a substance or process that is indicative of the presence of cancer in the body. A biomarker might be either a molecule secreted by a tumor or it can be a specific response of the body to the presence of cancer. Genetic, epigenetic, proteomic, glycomic, and imaging biomarkers can be used for cancer diagnosis, prognosis and epidemiology. These markers can be assayed in non-invasively collected biofluids. However, few cancer biomarkers are highly sensitive and specific for cancer detection at the present time. Consequently, biomarkers are not yet ready for routine use due to challenges in their clinical validation for early disease detection, diagnosis and monitoring to improve long-term survival of patients. View Full-Text
Keywords: biomarker; cancer; diagnosis; glycans; prognosis; validation biomarker; cancer; diagnosis; glycans; prognosis; validation
Show Figures

Figure 1

MDPI and ACS Style

Mishra, A.; Verma, M. Cancer Biomarkers: Are We Ready for the Prime Time? Cancers 2010, 2, 190-208. https://doi.org/10.3390/cancers2010190

AMA Style

Mishra A, Verma M. Cancer Biomarkers: Are We Ready for the Prime Time? Cancers. 2010; 2(1):190-208. https://doi.org/10.3390/cancers2010190

Chicago/Turabian Style

Mishra, Alok, and Mukesh Verma. 2010. "Cancer Biomarkers: Are We Ready for the Prime Time?" Cancers 2, no. 1: 190-208. https://doi.org/10.3390/cancers2010190

Find Other Styles

Article Access Map by Country/Region

1
Only visits after 24 November 2015 are recorded.
Back to TopTop